Senior-led IDE consulting for medical device and biotech companies preparing, strengthening, or defending an Investigational Device Exemption submission to the FDA.
Chosen for nearly two dozen FDA data-integrity audits.
Built for inspections, not just enrollment. FDA Inspected. Zero findings.
Decades guiding high‑stakes medtech and biotech programs.
Before a significant-risk medical device can enter a clinical trial in the United States, the FDA must approve an Investigational Device Exemption.
The IDE application is where your regulatory strategy, clinical study design, and device risk profile converge, and the decisions you make here shape the cost, timeline, and credibility of everything that follows.
Health Policy Associates (HPA) provides senior-led IDE consulting for sponsors who need more than a completed application. Whether you’re assessing your study’s risk classification, designing an Early Feasibility Study, preparing a full IDE submission, or responding to an FDA clinical hold, we work with your team to build an IDE that the FDA can approve and your clinical program can execute.
An IDE submission starts with one critical question: does your planned clinical investigation involve a significant-risk device or a nonsignificant-risk device?
The answer will dictate whether you need full FDA approval under 21 CFR 812. Get this wrong, and you might require a full IDE application that was never in the plan, delay the study’s start by months, or trigger enforcement actions that put the entire program at risk.
We work with sponsors to build the risk determination rationale, develop the IDE application (when one is required), and ensure the study design and supporting documentation reflect a program the FDA is prepared to approve.
When the regulatory and clinical pieces are built together from the start, the IDE submission is stronger, and the transition to trial execution is faster.
HPA’s IDE consulting covers the full range of regulatory, clinical, and operational decisions that determine whether a device can be clinically investigated in the U.S. We help sponsors navigate every step from the initial risk determination through post-approval amendments.
The distinction between a significant-risk device and a nonsignificant-risk device determines the entire regulatory pathway for your clinical study.
Significant-risk devices require a full IDE application with FDA approval before the study can begin, while nonsignificant-risk devices can proceed under IRB oversight alone — though the sponsor must still document the risk determination and be prepared to defend it.
We develop the rationale and supporting evidence so the classification will hold up, whether the FDA reviews it directly or questions it after the fact.
For significant-risk devices, we prepare and compile the IDE application under 21 CFR 812, including:
We ensure the application presents a coherent case, showing that:
An IDE application is only as strong as the clinical investigation it describes. We work with sponsors to design study protocols that are feasible, enrollable, and aligned with what the FDA expects to see.
When the study design is also shaped by a Pre-Submission interaction, we integrate the FDA’s feedback directly into the protocol and IDE application.
Early Feasibility Studies allow sponsors to begin clinical investigation earlier in development, with smaller patient populations and greater flexibility for design iteration. These studies carry their own IDE requirements and FDA expectations.
We support sponsors through the Early Feasibility IDE pathway, including study design, risk-benefit justification, and the additional regulatory documentation the FDA requires for investigational devices that are still evolving.
Once an IDE is approved, an IDE supplement may be required before any changes to the investigational plan, study protocol, device design, or manufacturing process can be implemented.
We prepare IDE supplements with the supporting rationale and documentation the FDA needs to evaluate the change, so modifications don’t stall enrollment or create compliance gaps.
We turn IDE requirements into a clear submission strategy and study plan, so your team knows exactly what the FDA needs before your first patient is enrolled.
We help you build an IDE that demonstrates your device is ready for clinical investigation, with a study design and evidence plan that holds up under FDA review.
HPA’s senior consultants stay with your program from risk determination through IDE approval and into trial execution, so regulatory and clinical efforts stay aligned.
The scope of an IDE engagement depends on where the sponsor is in development, what the FDA has already said, and whether a study risk determination has been made.
Typical engagements include some or all of the following.
01
We assess your device’s risk profile against FDA criteria, develop the significant-risk or nonsignificant-risk determination rationale, and map the regulatory pathway for your clinical investigation.
This will establish whether a full IDE application is required, whether IRB-only oversight is appropriate, and what evidence the FDA or IRB will need to see before the study can proceed.
02
We compile the IDE application, ensuring strategic alignment across all required sections, and review it with your team to screen for issues that could trigger a clinical hold.
Where appropriate, we also review applicable FDA guidance, relevant regulations under 21 CFR 812, and any prior FDA feedback to strengthen the submission before it is filed.
03
We prepare your team for any IDE-related FDA interactions, which may include Pre-Submission meetings, clinical hold responses, and deficiency communications.
For nonsignificant-risk studies proceeding under IRB oversight, we help document the risk determination so it is defensible if the FDA questions it later. We also provide executive summaries that explain the IDE status, study timeline, and regulatory risks in clear business language for investors and leadership.
Some IDE programs require support beyond risk determination and submission preparation. When the program demands it, we can extend the engagement to include:
when the sponsor needs end-to-end support in keeping the IDE’s regulatory commitments aligned with day-to-day trial operations, from protocol finalization through enrollment, monitoring, and closeout.
when the IDE is part of a broader development program and the sponsor needs help mapping the full path from clinical investigation through PMA or other marketing submission.
including gap assessments against 21 CFR Part 820 (QMSR) and ISO 13485 requirements, particularly when the IDE program will be subject to Bioresearch Monitoring (BIMO) inspections.
when the investigational device includes a drug or biologic constituent part and lead-center determination or cross-center coordination must be resolved.
We scope these extensions based on your program’s specific needs and can connect the work directly to our Clinical Trial Strategy & Execution, Medical Device Regulatory Consulting, Quality Systems & Compliance Consulting, and Combination Product Consulting services.
When your IDE program moves into active clinical investigation, we can extend the engagement into Clinical Trial Strategy & Execution so your regulatory commitments and trial operations stay aligned from IDE approval through study closeout.
An IDE submission is the gateway to clinical investigation, and the FDA will scrutinize whether your device is safe enough to test in patients.
When the device is novel, the risk profile is complex, or the study design is under pressure from investors and timelines, the cost of a preventable clinical hold or a poorly structured application isn’t just delay — it’s lost credibility with the FDA at a moment that defines the rest of the program.
HPA brings senior-led regulatory and clinical judgment to your IDE program so you can move from risk determination to an approved investigation with a plan your team, leadership, and investors can stand behind.